Abstract:Background : The 3C-like proteases (3CL pro s) are cysteine-rich homodimeric proteins and can be covalently modified by numerous natural and synthetic compounds, which in turn, block the proteolytic activity or the formation of enzymatically active dimeric forms. Although herbal medicines have been widely used to treat COVID-19, identification of the key herbal constituents that can covalently modify the 3CL pro s in β-coronaviruses (CoVs) remains a big challenge. Aims : To construct a comprehensive approach for efficient discovering the covalent SARS-CoV-2 3CL pro inhibitors from herbal medicines. To decipher the key anti-SARS-CoV-2 3CL pro constituents in Ginkgo biloba extract 50 (GBE50) and to study their anti-SARS-CoV-2 3CL pro mechanisms. Methods : SARS-CoV-2 3CL pro inhibition assay including time-dependent inhibition assays and inactivation kinetic analyses were conducted using a fluorescence-based biochemical assay. The constituents in GBE50 were analyzed by UHPLC-Q-Exactive Orbitrap HRMS. The peptides modified by herbal constituents were characterized by using nanoLC-MS/MS. Results : Following testing the anti-SARS-CoV-2 3CL pro effects of 104 herbal medicines, it was found that Ginkgo biloba extract 50 (GBE50) potently inhibited SARS-CoV-2 3CL pro in dose- and time-dependent manners. A total of 38 constituents were identified from GBE50 by UHPLC-Q-Exactive Orbitrap HRMS, while 26 peptides modified by 18 constituents were identified by chemoproteomic profiling. The anti-SARS-CoV-2 3CL pro effects of 18 identified covalent inhibitors were then validated by performing time-dependent inhibition assays. The results clearly demonstrated that most tested constituents showed time-dependent inhibition on SARS-CoV-2 3CL pro , while gallocatechin and sciadopitysin displayed the most potent anti-SARS-CoV-2 3CL pro effects. Conclusion : Collectively, GBE50 and some constituents in this herbal product could strongly inhibit SARS-CoV-2 3CL pro in dose- and time-dependent manner. Gallocatechin and sciadopitysin were identified as potent SARS-CoV-2 3CL pro inhibitors, which offers promising lead compounds for the development of novel anti-SARS-CoV-2 drugs.

Identification of Natural Compounds with Antiviral Activities Against Sars-Associated Coronavirus

Traditional Chinese Medicine Herbal Extracts of Cibotium Barometz, Gentiana Scabra, Dioscorea Batatas, Cassia Tora, and Taxillus Chinensis Inhibit SARS-CoV Replication

Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

An Integrated Method for Optimized Identification of Effective Natural Inhibitors Against SARS-CoV-2 3Clpro

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

Screening of Botanical Drugs Against SARS-CoV-2 Entry

Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells.

Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets

In Silico Identification of Anti-SARS-CoV-2 Medicinal Plants Using Cheminformatics and Machine Learning

Antiviral activities of medicinal herbs traditionally used in southern mainland China.

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Target-Based in Silico Screening for Phytoactive Compounds Targeting SARS-CoV-2

In Vitro Susceptibility of 10 Clinical Isolates of SARS Coronavirus to Selected Antiviral Compounds

Dual Assay Validation of Rosmarinus officinalis Extract as an Inhibitor of SARS‐CoV‐2 Spike Protein: Combining Pseudovirus Testing, Yeast Two‐Hybrid, and UPLC‐Q Exactive Orbitrap‐MS Profiling

In Silico Molecular Docking and Interaction Analysis of Traditional Chinese Medicines Against SARS-CoV-2 Receptor

Anti-coronavirus and anti-pulmonary inflammation effects of iridoids, the common component from Chinese herbal medicines for the treatment of COVID-19

Discovery of TCMs and derivatives against the main protease of SARS-CoV-2 via high throughput screening, ADMET analysis, and inhibition assay in vitro

Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19

Discovery and characterization of the covalent SARS-CoV-2 3CL pro inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches

Discovery and Characterization of the Covalent SARS-CoV-2 3clpro Inhibitors from Ginkgo Biloba Extract Via Integrating Chemoproteomic and Biochemical Approaches

The discovery of herbal drugs and natural compounds as inhibitors of SARS-CoV-2 infection in vitro